– Istituto Nazionale dei Tumori –
The antigen-binding fragment (scFv) of a monoclonal antibody that recognizes prostate-specific membrane antigen (PSMA) on the surface of tumor cells has been patented.
The complete antibody and its scFv fragment can be used alone or conjugated with radioactive, cytotoxic or fluorescent substances for the diagnosis, staging and treatment of prostate tumors that express the PSMA antigen
Applications
- Development of specific radiopharmaceuticals for the diagnosis and treatment of prostate cancer.
- Development of cytotoxic immunotoxins for prostate cancer therapy.
- Development of CAR-T for immunotherapy treatment.
Key benefits
- Technology that can be easily used by hospital professionals.
- Better clinical outcome for patients due to reduced exposure to radioactive reagent during imaging.
- Greater tissue penetration, maximum recognition specificity, fast unbound clearance and reduced toxicity in therapy.
Offer
- Licensing out.
- Co-Development.